NEW ORLEANS (Reuters) - Sanofi-Aventis's experimental drug Multaq significantly reduced the incidence of hospitalization and length of hospital stays in patients with atrial fibrillation, according to ...
The Food and Drug Administration says an experimental drug from Sanofi-Aventis could significantly decrease hospitalizations caused by irregular heart rhythms. Subscribe to read this story ad-free Get ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results